Tonix Secures Medicare Part D Coverage for TONMYA, Expanding Access to 145M Lives
TNXP sits 32% above its 52-week low of $10.03.
Summary
Tonix Pharmaceuticals has secured a Medicare Part D payer agreement for its fibromyalgia drug TONMYA, adding coverage for approximately 9 million beneficiaries effective January 1, 2027. This builds on prior commercial and Medicaid wins, bringing total covered lives to an expected 145 million—roughly 46% of U.S. covered lives—on that date. The company is also expanding its sales force by about 50 representatives to 150 total, with deployment planned by mid-Q3 2026. The news follows a series of positive coverage announcements and a recent $22.6 million capital raise, but the company still carries a going-concern warning and significant cash burn. The expanded coverage and sales force signal a serious commercial push for TONMYA, which could materially improve revenue trajectory if uptake meets expectations.
At the time of this announcement, TNXP was trading at $13.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $199.7M. The 52-week trading range was $10.03 to $69.97. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.